FrancophonIA/ELRC3.0 huggingface dataset:
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Luveniq can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Estonian: Harvikravimite komitee arvamuse kokkuvõte Luveniqi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: Withdrawal of the marketing authorisation application for Luveniq (voclosporin) EMA/CHMP/835463/2011
Estonian: Müügiloa taotluse tagasivõtmise teave: Luveniq (voklosporiin) EMA/CHMP/835463/2011
English: Luveniq is an immunosuppressive agent, which means that it reduces the activity of the immune system.
Estonian: Luveniq on immuunsupressiivse toimega, mis tähendab, et see vähendab immuunsüsteemi aktiivsust.
English: Luveniq also caused side effects which are known to occur with this type of immunosuppressive medicine, including hypertension (high blood pressure).
Estonian: Lisaks põhjustas Luveniq kõrvalnähte, mis teadaolevalt ilmnevad seda tüüpi immuunsupressiivse ravimi kasutamisel, sealhulgas hüpertensiooni (kõrge vererõhk).
English: It belongs to the class of calcineurin inhibitors.
Estonian: Ravim kuulub kaltsineuriiniinhibiitorite klassi.
English: Withdrawal of the marketing authorisation application for Luveniq (voclosporin)
Estonian: Müügiloa taotluse tagasivõtmise teave: Luveniq (voklosporiin)
English: It is called ‘non-infectious' when it is caused by the body's own immune system (the body's natural defences) attacking the uvea.
Estonian: Haigus on mittenakkuslik, kui seda põhjustab organismi enda immuunsüsteem (organismi loomulik kaitsemehhanism), mis ründab uuveat.
English: The application was supported by one main study involving 218 patients with non-infectious uveitis which compared Luveniq with placebo.
Estonian: Taotlust toetas üks põhiuuring, kus osales 218 mittenakkusliku uveiidiga patsienti ja kus Luveniqi võrreldi platseeboga.
English: Only one main study supported the application and the results did not show in a robust way that Luveniq was more effective than placebo at reducing eye inflammation, while no difference was seen in the patients' eyesight compared with placebo.
Estonian: Taotlust toetas ainult üks põhiuuring ja selle tulemused ei näidanud kindlalt, et Luveniq vähendab silmapõletikku efektiivsemalt kui platseebo, sest platseeboraviga võrreldes ei olnud patsientide silmanägemises mingit erinevust.
English: The main measure of effectiveness was how the inflammation of the eye improved after 16 weeks and 24 weeks of treatment, measured by looking at the change in the amount of vitreous haze (clouding of the vitreous humour, the clear gel between the lens and the retina of the eyeball).
Estonian: Efektiivsuse põhinäitaja oli silmapõletiku paranemine 16 ja 24 ravinädala pärast, mida hinnati klaaskeha (läbipaistev sültjas ollus silmaläätse ja võrkkesta vahel) hägususe muutuste põhjal.
English: It targets T-cells, a type of white blood cell in the immune system that is particularly active in inflammation.
Estonian: See toimib T-rakkude suhtes (teatud valgelibled immuunsüsteemis), mis osalevad eriti aktiivselt põletikuprotsessis.
English: Therefore, the CHMP was of the opinion that the benefits of Luveniq had not been shown to outweigh its risks and recommended that it be refused marketing authorisation.
Estonian: Seetõttu oli inimravimite komitee arvamusel, et ravimi Luveniq kasulikkus ei ole tõendatult suurem kui sellega kaasnevad riskid, ega soovitanud anda ravimile müügiluba.
English: Luveniq is a medicine that contains the active substance voclosporin.
Estonian: Luveniq on ravim, mille toimeaine on voklosporiin.
English: Luveniq was designated an ‘orphan medicine' (a medicine to be used in rare diseases) on 14 September 2007 for the treatment of chronic non-infectious uveitis.
Estonian: Luveniq nimetati 14. septembril 2007 korduva mittenakkusliku uveiidi harvikravimiks (ravim, mida kasutatakse harvaesinevate haiguste korral).
English: Based on the review of the data, at the time of the withdrawal, the CHMP had previously given a negative opinion in June 2011 recommending that the marketing authorisation be refused for Luveniq for the treatment of chronic active non-infectious uveitis involving the intermediate or posterior segments of the eye.
Estonian: Tuginedes esitatud andmete analüüsile, oli komitee andnud enne taotluse tagasivõtmist negatiivse arvamuse 2011. aasta juunis ega soovitanud anda ravimile Luveniq silma korduva ägeda mittenakkusliku intermediaalse või posterioorse uveiidi raviks müügiluba.
English: The company informed the CHMP that there are no consequences for patients included in ongoing clinical trials.
Estonian: Ettevõte teatas inimravimite komiteele, et taotluse tagasivõtmine ei mõjuta praegu Luveniqi kliinilistes uuringutes osalevaid patsiente.
English: The effects of Luveniq were first tested in experimental models before being studied in humans.
Estonian: Enne inimuuringuid kontrolliti Luveniqi toimet muude katsetega.
English: It was expected to decrease the inflammation seen in uveitis by blocking an enzyme called calcineurin which is involved in activating Tcells.
Estonian: Luveniq pidi vähendama põletikku uveiidi korral, blokeerides T-rakkude aktiveerimises osaleva ensüümi kaltsineuriini.
English: How is Luveniq expected to work?
Estonian: Milline on Luveniqi eeldatav toime?
English: On 13 October 2011, Lux Biosciences GmbH officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Luveniq, for the treatment of chronic active non-infectious uveitis involving the intermediate or posterior segments of the eye.
Estonian: Ettevõte Lux Biosciences GmbH teatas 13. oktoobril 2011 ametlikult inimravimite komiteele oma soovist võtta tagasi ravimi Luveniq müügiloa taotlus.
English: What was Luveniq expected to be used for?
Estonian: Milleks kavatseti Luveniqi kasutada?
English: At the time of the negative opinion, the CHMP was not convinced that the benefits of Luveniq had been shown to outweigh the risks as a treatment for chronic non-infectious uveitis.
Estonian: Negatiivse arvamuse andmise ajal ei olnud inimravimite komitee veendunud, et Luveniqi kasulikkus korduva mittenakkusliku uveiidi ravis on tõendatult suurem kui sellega kaasnevad riskid.
English: Luveniq was expected to be used to treat chronic active non-infectious uveitis involving the intermediate or posterior segments of the eye. Uveitis is inflammation of the uvea (the middle layer of the eye) which can lead to loss of vision.
Estonian: Luveniqi kavatseti kasutada silma korduva ägeda mittenakkusliku intermediaalse või posterioorse uveiidi raviks.
English: EU/1/11/742/001
Estonian: (PVC/PVDC/alu)
English: Efavirenz Teva
Estonian: Õhukese blister
English: The European Commission granted a marketing authorisation valid throughout the European Union for Rasilamlo on 14 April 2011.
Estonian: Euroopa Komisjon andis Rasilamlo müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 14. aprillil 2011.
English: The full EPAR for Rasilamlo can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Rasilamlo kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: Rasilamlo is for use in adults only; it must not be used in children aged less than 2 years and is not recommended for older children.
Estonian: Rasilamlo on ette nähtud ainult täiskasvanutele; seda ei tohi kasutada alla 2-aastased lapsed ja seda ei soovitata vanematele lastele.
English: A risk management plan has been developed to ensure that Rasilamlo is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Rasilamlo võimalikult ohutu kasutamine.
English: What measures are being taken to ensure the safe and effective use of Rasilamlo?
Estonian: Mis meetmed võetakse, et tagada Rasilamlo ohutu ja efektiivne kasutamine?
English: Other information about Rasilamlo
Estonian: Muu teave Rasilamlo kohta
English: Rasilamlo aliskiren / amlodipine
Estonian: Rasilamlo aliskireen / amlodipiin
English: In three main studies involving 2,212 patients Rasilamlo was compared with aliskiren or amlodipine taken alone for eight or six weeks.
Estonian: Kolmes põhiuuringus, kus osales 2212 patsienti, võrreldi Rasilamlot aliskireeni või amlodipiiniga, mida võeti eraldi kaheksa või kuus nädalat.
English: The CHMP decided that Rasilamlo's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Rasilamlo kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: The main measure of effectiveness was the change in the average diastolic blood pressure (blood pressure measured between two heartbeats) measured when the patients were seated.
Estonian: Efektiivsuse põhinäitaja oli patsiendi istudes mõõdetud keskmise diastoolse vererõhu (vererõhk südamelöökide vahelisel ajal) muutus.
English: The most common side effects with Rasilamlo are hypotension (low blood pressure) and peripheral oedema (swelling, especially of the ankles and feet).
Estonian: Rasilamlo kõige sagedamad kõrvalnähud on hüpotensioon (madal vererõhk) ja perifeerne ödeem (eelkõige pahkluude ja labajalgade turse).
English: What is the risk associated with Rasilamlo?
Estonian: Mis riskid Rasilamloga kaasnevad?
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Rasilamlo, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Rasilamlo omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: Why has Rasilamlo been approved?
Estonian: Miks Rasilamlo heaks kiideti?
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Rasilamlo.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: By reducing the flow of calcium into the cells, amlodipine prevents the blood vessel walls from contracting, thus lowering the blood pressure.
Estonian: Vähendades kaltsiumi sissevoolu rakkudesse, ennetab amlodipiin veresoonte seinte kokkutõmbumist, mis alandab vererõhku.
English: For more information about treatment with Rasilamlo, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Rasilamloga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: This is a summary of the European public assessment report (EPAR) for Rasilamlo.
Estonian: See on ravimi Rasilamlo Euroopa avaliku hindamisaruande kokkuvõte.
English: It should not be taken together with fruit juice or drinks containing plant extracts such as herbal teas.
Estonian: Rasilamlo manustamise ajal ei tohi juua puuviljamahla ega taimeekstrakte sisaldavaid jooke, näiteks taimeteed.
English: For the full list of all side effects reported with Rasilamlo, see the package leaflet.
Estonian: Rasilamlo kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: It must also not be used in women who are more than three months pregnant or in patients taking medicines containing ciclosporin, itraconazole or other medicines known as ‘potent Pglycoprotein inhibitors' (such as quinidine).
Estonian: Samuti ei tohi ravimit kasutada üle kolme kuu rasedad ega patsiendid, kes võtavad ravimeid, mis sisaldavad tsüklosporiini, itrakonasooli või teisi tugevaid P-glükoproteiini inhibiitoreid (nt kinidiin).
English: Rasilamlo is used to treat essential hypertension (high blood pressure) in adults whose blood pressure is not adequately controlled with aliskiren or amlodipine used alone.
Estonian: Rasilamlot kasutatakse essentsiaalse hüpertensiooni (kõrgvererõhutõve) raviks täiskasvanutel, kelle vererõhk ei allu piisavalt ravile üksnes aliskireeni või amlodipiiniga.
English: It must not be used in patients with a history of angioedema (swelling beneath the skin) with aliskiren, hereditary angioedema or angioedema of no obvious cause, severe hypotension, shock, narrowing of the aortic heart valve or in patients with heart failure after a heart attack.
Estonian: Seda ei tohi kasutada patsiendid, kellel on aliskireeni manustamisel varem tekkinud angioödeem (nahaalune turse), kellel on pärilik angioödeem või angioödeem teadmata põhjusel, raske hüpotensioon, šokk või südame aordiklapi ahenemine, ega ka patsiendid, kellel on südameataki järel tekkinud südamepuudulikkus.
English: It is available as tablets (150 mg aliskiren and 5 mg amlodipine; 150 mg aliskiren and 10 mg amlodipine; 300 mg aliskiren and 5 mg amlodipine; 300 mg aliskiren and 10 mg amlodipine).
Estonian: Seda turustatakse tablettidena (150 mg aliskireeni ja 5 mg amlodipiini; 150 mg aliskireeni ja 10 mg amlodipiini; 300 mg aliskireeni ja 5 mg amlodipiini; 300 mg aliskireeni ja 10 mg amlodipiini).
English: What is Rasilamlo?
Estonian: Mis on Rasilamlo?
English: The dose may be adjusted based on the side effects the patient experienced with their previous treatment with aliskiren or amlodipine and also on how the patient responds to treatment with Rasilamlo.
Estonian: Annust võib kohandada kõrvalnähtude alusel, mis patsiendil varasema aliskireeni või amlodipiini ravi ajal tekkisid, sõltuvalt patsiendi ravivastusest ravile Rasilamloga.
English: Rasilamlo is a medicine that contains the active substances aliskiren and amlodipine.
Estonian: Rasilamlo on ravim, mis sisaldab toimeainetena aliskireeni ja amlodipiini.
English: Rasilamlo must not be used in people who are hypersensitive (allergic) to aliskiren, amlodipine, to any of the other ingredients of the medicine or other substances derived from dihydropyridine (a group that includes amlodipine).
Estonian: Rasilamlot ei tohi kasutada patsiendid, kes on aliskireeni, amlodipiini või selle ravimi mis tahes muu koostisaine või teiste dihüdropüridiini derivaatide (ravimirühm, kuhu kuulub amlodipiin) suhtes ülitundlikud (allergilised).
English: Rasilamlo contains two active substances, aliskiren and amlodipine.
Estonian: Rasilamlo sisaldab kahte toimeainet, aliskireeni ja amlodipiini.
English: The strength of the tablet the patient takes depends on the doses of aliskiren or amlodipine that they received previously.
Estonian: Võetava tableti tugevus sõltub patsiendi varasemast aliskireeni või amlodipiini annusest.
English: How does Rasilamlo work?
Estonian: Kuidas Rasilamlo toimib?
English: Rasilamlo can be used with other antihypertensive medicines, with the exception of ‘angiotensin converting enzyme (ACE) inhibitors' or ‘angiotensin receptor blockers' (ARBs) in patients with diabetes, or moderate or severe kidney impairment.
Estonian: Rasilamlot võib kasutada koos muude kõrgvererõhuravimitega, v.a angiotensiini muundava ensüümi (ACE) inhibiitorite või angiotensiini retseptori blokaatoritega (ARB), kui patsiendil on diabeet või mõõdukas kuni raske neerukahjustus.
English: Rasilamlo in combination with an ACE inhibitor or an ARB must not be used in patients with diabetes, or moderate or severe kidney impairment.
Estonian: Rasilamlot ei tohi kasutada koos ACE-inhibiitori ega ARB-ga, kui patsiendil on diabeet või mõõdukas kuni raske neerukahjustus.
English: In the first study, patients taking Rasilamlo 300/10 mg and 300/5 mg had a fall in their sitting diastolic blood pressure of 13.1 mmHg and 10.5 mmHg, respectively, compared with a fall of 5.8 mmHg in patients taking aliskiren 300 mg.
Estonian: Esimeses uuringus langes 300/10 mg või 300/5 mg Rasilamlot võtnud patsientide istudes mõõdetud diastoolne vererõhk vastavalt 13,1 mmHg või 10,5 mmHg, võrreldes vererõhu langusega 5,8 mmHg patsientidel, kes võtsid 300 mg aliskireeni.
English: Rasilamlo was more effective at controlling essential hypertension than placebo, aliskiren or amlodipine used alone.
Estonian: Rasilamlo aitas essentsiaalset hüpertensiooni kontrollida efektiivsemalt kui platseebo või aliskireen või amlodipiin eraldi ravimitena.
English: What benefit has Rasilamlo shown during the studies?
Estonian: Milles seisneb uuringute põhjal Rasilamlo kasulikkus?
English: It blocks the activity of a human enzyme called renin, which is involved in the production of a substance called angiotensin I in the body.
Estonian: Aliskireen on reniini inhibiitor ehk aine, mis blokeerib organismis angiotensiin I tekkes osaleva inimensüümi reniini toime.
English: It blocks special channels on the surface of cells called calcium channels, through which calcium ions normally enter.
Estonian: Amlodipiin on kaltsiumikanali blokaator ehk aine, mis blokeerib rakupinnal olevaid kaltsiumikanaleid, mille kaudu kaltsiumiioonid tavaliselt sisenevad rakku.
English: The third study showed a fall in blood pressure of 8.5 mmHg with Rasilamlo 150/5 mg compared with 8.0 mmHg and 4.8 mmHg with amlodipine 10 mg and 5 mg, respectively.
Estonian: Kolmandas uuringus oli vererõhu langus 8,5 mmHg patsientidel, kes võtsid 150/5 mg Rasilamlot, võrreldes vererõhu langusega 8,0 mmHg või 4,8 mmHg patsientidel, kes võtsid vastavalt 10 mg või 5 mg amlodipiini.
English: In the second study the falls in blood pressure were 11.0 mmHg and 9.0 mmHg with Rasilamlo 300/10 mg and 150/10mg, respectively, compared with 7.2mmHg with amlodipine 10 mg.
Estonian: Teises uuringus oli vererõhu langus 11,0 mmHg või 9,0 mmHg patsientidel, kes võtsid vastavalt 300/10 mg või 150/10 mg Rasilamlot, võrreldes vererõhu langusega 7,2 mmHg patsientidel, kes võtsid 10 mg amlodipiini.
English: How has Rasilamlo been studied?
Estonian: Kuidas Rasilamlot uuriti?
English: The medicine can only be obtained with a prescription.
Estonian: Rasilamlo on retseptiravim.
English: What is Rasilamlo used for?
Estonian: Milleks Rasilamlot kasutatakse?
English: How is Rasilamlo used?
Estonian: Kuidas Rasilamlot kasutatakse?
English: If this happens, do not drive or use any tools or machines until you are feeling well again.
Estonian: Kui see juhtub teiega, siis ärge juhtige autot ega kasutage mingeid tööriistu või masinaid kuni te end jälle hästi tunnete.
English: (Best response rates)
Estonian: (Parim reaktsioon)
English: The doctor will monitor the growth at regular visits.
Estonian: Arst jälgib kasvu korralistel visiitidel.
English: - If you forget a dose, take it as soon as you remember.
Estonian: - Kui te unustate ühe annuse võtta, võtke see kohe, kui see teile meenub.
English: In the rest of this leaflet, we will use the abbreviations when talking about these diseases.
Estonian: Antud infolehes kasutame edaspidi nendest haigustest rääkides lühendeid.
English: • Stir with a spoon until the tablets have completely dissolved.
Estonian: • Segage lusikaga kuni tabletid on täielikult lahustunud.
English: - Swallow the tablets whole with a large glass of water.
Estonian: Neelake tabletid tervelt koos suure klaasitäie veega.
English: OTHER SPECIAL WARNING(S), IF NECESSARY Use only as directed by a doctor.
Estonian: TEISED ERIHOIATUSED (VAJADUSEL) Kasutada ainult vastavalt arsti juhistele.
English: Similar findings were found based on a 18-months landmark analysis.
Estonian: Samasugused tulemused saadi ka 18 kuu andmete analüüsil.
English: Imatinib n=553
Estonian: Imatiniib n=553
English: • Unexpected bleeding or bruising (when you have not hurt yourself).
Estonian: • Ootamatu verejooks või verevalum (kui te ei ole ennast vigastanud).
English: Date of first authorization: 01 July 2013 Date of latest renewal: 19th April 2018
Estonian: Müügiloa viimase uuendamise kuupäev: 19. aprill 2018
English: • Do not use any pack that is damaged or shows signs of tampering.
Estonian: • Ärge kasutage ühtegi pakendit, mis on kahjustatud või rikkumise tunnustega.
English: A confirmed haematological response was achieved in 71.5% of patients (Table 3).
Estonian: Kinnitunud hematoloogiline vastus saavutati 71,5% patsientidel (table 3).
English: Other medicines and Imatinib Accord
Estonian: Muud ravimid ja Imatinib Accord
English: Tell your doctor straight away if you get any of the following
Estonian: Teavitage oma arsti otsekohe, kui teil tekib ükskõik milline järgnevatest seisunditest
English: If you have accidentally taken too many tablets, talk to your doctor straight away.
Estonian: Kui võtsite kogemata liiga palju tablette, võtke viivitamatult ühendust arstiga.
English: If you have any questions about how Imatinib Accord works or why this medicine has been prescribed for you, ask your doctor.
Estonian: Kui teil on küsimusi, kuidas Imatinib Accord toimib või miks see ravim on teile määratud, pöörduge oma arsti poole.
English: • Once the tablet has dissolved, drink everything in the glass straight away.
Estonian: • Kui tablett on lahustunud jooge koheselt kogu klaasi sisu ära.
English: Imatinib Accord can help you to fight this condition.
Estonian: Imatinib Accord võib aidata teil selle haigusega võidelda.
English: Ki values in human liver microsomes were 27, 7.5 and 7.9 mol/l, respectively.
Estonian: Ki väärtused inimese maksa mikrosoomides olid vastavalt 27, 7,5 ja 7,9 mikromol/l.
English: Haematological response criteria (all responses to be confirmed after ≥ 4 weeks):
Estonian: 1 1 Hematoloogilise ravivastuse kriteeriumid (kõik ravivastused kinnituvad pärast 4 nädalat):
English: However, always take this medicine exactly as your doctor or pharmacist has told you.
Estonian: Võtke seda ravimit alati täpselt nii, nagu arst või apteeker on teile selgitanud.
English: • Do not use this medicine after the expiry date which is stated on the carton and blister after
Estonian: • Ärge kasutage seda ravimit pärast kõlblikkusaega, mis on märgitud karbil ja blistril pärast
English: For CML, your doctor may prescribe a higher or lower dose depending on how you respond to the treatment.
Estonian: KMLi korral võib arst teile määrata suurema või väiksema annuse, sõltuvalt sellest, milline on teie ravivastus.
English: Increased blood urea nitrogen (BUN) and creatinine were observed in several of these animals.
Estonian: Vere uurea (blood urea nitrogen, BUN) ja kreatiniini tõusu täheldati mitmel loomal.
English: 319 Pinner Road North Harrow Middlesex, HA1 4HF United Kingdom
Estonian: 319 Pinner Road North Harrow Middlesex, HA1 4HF Ühendkuningriik
English: If you are unable to swallow the tablets, you can dissolve them in a glass of still water or apple juice:
Estonian: Kui te ei suuda tablette neelata, võite need lahustada klaasi gaseerimata vee või õunamahla hulka:
English: Studies on patients receiving Imatinib Accord and its effect on fertility and gametogenesis have not been performed.
Estonian: Uuringuid Imatinib Accord'i saanud patsientidel ja selle mõju kohta fertiilsusele ja gametogeneesile ei ole läbi viidud.
English: Your doctor has prescribed Imatinib Accord because you suffer from a serious condition.
Estonian: Arst on teile määranud Imatinib Accord'i, kuna teil on tõsine haigus.
English: Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription (such as paracetamol) and including herbal medicines (such as St. John's Wort).
Estonian: Teatage oma arstile või apteekrile, kui te kasutate, või olete hiljuti kasutanud või kavatsete kasutada mis tahes muid ravimeid, kaasa arvatud ilma retseptita ostetud ravimeid (nagu paratsetamool), sealhulgas ravimtaimi (nagu naistepuna).
English: • Eye pain or deterioration in vision, bleeding in the eyes.
Estonian: • Valu silmades või nägemise halvenemine, verejooks silmades.
English: 260 patients with myeloid blast crisis were enrolled.
Estonian: Osales 260 müeloidse blastse kriisiga patsienti.
English: Mean absolute bioavailability for imatinib is 98%.
Estonian: Imatiniibi kasutamisel on keskmine absoluutne biosaadavus 98%.